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Abstract
Prions are unorthodox pathogens that cause fatal neurodegenerative diseases in humans
and other mammals. Prion propagation occurs through the self-templating of the pathogenic
conformer PrPSc, onto the cell-expressed conformer, PrPC. Here we study the conversion of
PrPC to PrPSc using a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc)
as a unique tool that can convert bank vole but not mouse PrPC substrates in vitro. Thus, its
templating ability is not dependent on sequence homology with the substrate. In the present
study, we used chimeric bank vole/mouse PrPC substrates to systematically determine the
domain that allows for conversion by Mo protein-only recPrPSc. Our results show that that
either the presence of the bank vole amino acid residues E227 and S230 or the absence of
the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo
protein-only recPrPSc and several native infectious prion strains. We propose that residues
227 and 230 and the second glycan are part of a C-terminal domain that acts as a linchpin
for bank vole and mouse prion conversion.
Author summary
Prions are unconventional infectious agents that lack nucleic acids such as DNA and
RNA, and the mechanism by which prions replicate is not fully understood. It has been
established that a central feature of the replication mechanism involves the misfolding of a
host protein (PrPC) into an infectious shape termed PrPSc, but it is unclear how this mis-
folding occurs. Interestingly, it has been observed that a particular animal species, the
European bank vole, is unusually susceptible to prion infection and that this near-univer-
sal susceptibility is caused by the specific PrPC sequence of this protein. Here we use a
powerful and unique biochemical system to determine the specific region of bank vole
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PrPC that is primarily responsible for its propensity to misfold into PrPSc. This critical
region, which is located at the extreme C-terminal end of the protein, appears to act as a
linchpin domain that normally stabilizes the shape of PrPC and thereby regulates its mis-
folding into PrPSc.
Introduction
Prions are unorthodox infectious agents of fatal neurological diseases that affect many mam-
malian species, including humans. The central pathogenic event underlying prion infection is
the self-propagating conformational change of a host-encoded glycoprotein (PrPC) into a mis-
folded conformer (PrPSc)[1].
The protein-only hypothesis states that infectious prions are composed solely of PrPSc[2, 3].
However, much evidence indicates that cofactor molecules are required for the formation of
infectious prions[4–7]. In direct support of this concept, our laboratory generated two self-
propagating bacterially-expressed recombinant (rec) PrPSc conformers (cofactor recPrPSc and
protein-only recPrPSc) by propagating the same original seed in the presence and absence of
purified phospholipids, respectively[7, 8]. Whereas cofactor recPrPSc effectively seeds mouse
(Mo) brain homogenate (BH) sPMCA reactions in vitro and potently infects wild-type mice in
vivo, protein-only recPrPSc cannot seed Mo BH sPMCA reactions and fails to infect wild-type
mice[7].
Most animal species have transmission barriers that render them resistant to the majority
of prion strains from other species. Some species, such as rabbits, dogs, and horses are resistant
to naturally occurring prion strains[9]. In contrast, the European bank vole (Myodes glareolus)
is a highly susceptible host for a wide variety of prion diseases[10–14]. Experiments with trans-
genic mice showed that the susceptibility of bank voles to prion infection is ultimately encoded
by the amino acid sequence of bank vole (BV) PrPC[13, 15], and BV PrP has been shown to be
a highly susceptible substrate for in vitro conversion assays [16]. Several residues and domains
in the BV PrPC sequence have previously been identified through in vitro and in vivo
approaches to play important roles in the susceptibility by specific prions from other species
[17–22]. While the residues and domains identified in these experiments appear to play roles
for the specific species barriers studied, it is difficult to distinguish whether they do so because
of sequence mismatch between seed and substrate or because they control the structural transi-
tion of PrPC to PrPSc.
Recently, we discovered that protein-only recPrPSc is able to potently seed BV but not Mo
PrPC substrate in sPMCA reactions, and the PrPSc molecules produced in these reactions are
highly infectious[23]. Interestingly, we observed that the formation of infectious PrPSc mole-
cules from non-infectious protein-only recPrPSc seed required several factors: (1) bank vole
rather than mouse PrPC substrate, (2) native PrPC rather than recPrP substrate lacking post-
translational modifications (PTMs), and (3) cofactor molecules.
In the present study, we exploit this system to identify PrPC domains that might serve as
“linchpins” to control PrP conformational change. Uniquely, this system has the critical
advantage of not being influenced by species barriers[24] since mouse protein-only recPrPSc
can seed BV PrPC but not Mo PrPC in this system. Therefore, we can test the ability of native
Mo-BV PrPC chimeric substrates to convert in sPMCA reactions driven by Mo protein-only
recPrPSc seed, with confidence that this process depends only upon the enhanced ability of BV
PrPC (and chimeric substrates) to convert into PrPSc, rather than the degree of amino acid
sequence similarity between seed and substrate. Similarly, this system also provides a unique
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opportunity to study the effect of PTMs on PrPSc formation since protein-only recPrPSc,
which lacks PTMs, requires native PrPC substrate to produce PrPSc.
Results
BV PrP is uniquely able to propagate Mo protein-only recPrPSc
The amino acid sequence of the processed region of BV PrP is a natural chimera of Mo PrP
and Ha PrP, with the exception of two unique residues at the extreme C-terminus (Fig 1A). As
a preliminary experiment, we first compared the conversion ability of BV BH, Ha BH, and Mo
BH to propagate Mo protein-only recPrPSc. The results show that BV BH, but not Ha BH or
Mo BH, is capable of propagating Mo protein-only recPrPSc (Fig 1B, third column). BV BH is
Fig 1. Susceptibility of various rodent species in BH sPMCA. (A) Amino acid comparison of the processed regions of Mo PrP,
Ha PrP, and BV PrP. The sequence bar highlights the regions of BV PrP homologous to Mo PrP (orange) or Ha PrP (green), or
are unique to BV PrP (blue). Black arrowheads denote the location of N-linked glycans. The locations of various structural
domains are shown in black. OR = octapeptide repeat; PB = polybasic domain; GPI = glycophosphaditylinositol. Sequence
alignments were performed using Multalin[25]. (B) Western blots showing three-round sPMCA reactions using normal brain
homogenates (BH) from the species used in (A) as the substrates and initially seeded on day 0 with various seeds, as indicated. Day
0 samples are seeded reactions not subject to sonication. -PK = samples not subjected to proteinase K digestion; all other samples
were proteolyzed.
https://doi.org/10.1371/journal.ppat.1008875.g001
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also capable of propagating both the hamster prion strain 139H and the mouse prion strain
RML. In contrast, Mo BH is capable of propagating only RML, and Ha BH is capable of propa-
gating only 139H (Fig 1B). Taken together, these results show that BV PrP is a uniquely sus-
ceptible substrate to Mo protein-only recPrPSc and native prion strains from other species.
We next developed a system that allowed us to design and produce a wide variety of PrPC
substrates in HEK 293 cells. HEK 293 are human cells that can express secretory and mem-
brane-bound proteins with post-translational modifications, including N-linked glycans and a
GPI anchor[26, 27], at high level. All HEK-expressed constructs were partially deglycosylated
using PNGase F as previously described (S1 Fig) to improve the conversion efficiency of Mo
PrPC[28] (S2 Fig). This effect is likely due to the previously observed inhibitory effects of PrPC
glycosylation on the propagation of mouse prion strains[28, 29], which may be due to nega-
tively charged sialic acid groups within the glycan structure[30], and which may be further
aggravated by hyper-glycosylation in HEK 293 cells. To ensure our system faithfully repro-
duces similar seed specificity as brain homogenate substrates in sPMCA, we first tested the sus-
ceptibility of cell-expressed BV PrP and Mo PrP in sPMCA (Fig 2). The susceptibility of each
construct was tested in three-round reconstituted BH sPMCA reactions containing PrP0/0
brain homogenate and a partially purified PrPc construct. The results show that, like the crude
BH substrates, cell-expressed BV PrPC is capable of propagating Mo protein-only recPrPSc,
139H, and RML (Fig 2, top row). Cell-expressed BV PrPC can also propagate Mo cofactor
recPrPSc. However, significant PrPSc formation was not observed in either the 139H-seeded or
Mo cofactor recPrPSc seeded lanes until round 3 of sPMCA (Fig 2, top row, second and third
panels). In contrast, cell-expressed Mo PrPC was capable of propagating RML and Mo cofactor
recPrPSc, but not Mo protein-only recPrPSc or 139H (Fig 2, bottom row). Taken together, the
results show that the cell-expressed PrPC substrates have similar susceptibilities to crude BH
substrates from the same species.
BV PrP C-terminal domain is required for efficient conversion of sPMCA
reactions seeded with Mo protein-only recPrPSc
To identify the specific amino acid residue(s) required to enable BV PrPC to propagate Mo
protein-only recPrPSc, we designed a series of chimeric constructs based on the BV PrPC back-
bone sequence that, working from the C- towards the N- terminus, become progressively
substituted with Mo PrP residues (Fig 3A), and tested the ability of these chimeric constructs
to be seeded by Mo protein-only recPrPSc in sPMCA reactions. Within this systematic
Fig 2. Susceptibility of BV PrPC and Mo PrPC substrates in reconstituted sPMCA. Western blots showing three-
round reconstituted sPMCA reactions using either BV or Mo partially purified PrPC substrates supplemented with
PrP0/0 BH and seeded with various seeds, as indicated. -PK = samples not subjected to proteinase K digestion; all other
samples were proteolyzed.
https://doi.org/10.1371/journal.ppat.1008875.g002
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paradigm, BV PrP substitution(s) that are specifically required to propagate Mo protein-only
recPrPSc are identified when the resulting chimera is no longer capable of propagating Mo pro-
tein-only recPrPSc. The results show that substitution of residues 227 and 230 from BV
Fig 3. Determining the minimum PrP sequence required for propagation of Mo protein-only recPrPSc seed. (A)
Table summarizing the ability of various BV/Mo PrPC chimeras to propagate Mo protein-only recPrPSc. All constructs
in this series are based on the BV PrPC backbone and become progressively substituted with Mo residues from the C-
terminus towards the N-terminus, except for the last two constructs which contain different combinations of 3 Mo
substitutions. (B) Western blots of experiments summarized in (A), showing three-round reconstituted sPMCA
reactions using partially purified PrPC substrates supplemented with PrP0/0 BH and seeded with various seeds, as
indicated. -PK = samples not subjected to proteinase K digestion; all other samples were proteolyzed.
https://doi.org/10.1371/journal.ppat.1008875.g003
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sequence to Mo sequence (i.e. E227D and S230R) inhibited conversion of Mo protein-only
recPrPSc seeded reactions by >10-fold (Fig 3A, third row), chimera BV(DR)). We observed
some variability in sPMCA patterns obtained with BV(DR) substrate from experiment-to-
experiment; we detected no bands at all in round three in 3/5 Mo protein-only recPrPSc-seeded
independent sPMCA experiments. In other cases, such as the example shown (Fig 3B, second
row right panel), we observed a near-complete absence of the ~24 kDa PK-resistant by round
three of the reaction, while the lower molecular weight bands at ~16 and 19 kDa are present in
round three, but have reduced signal intensity. In comparison, the positive control reaction
containing BV(DR) PrPC and seeded with RML PrPSc showed consistent three-round propa-
gation (Fig 3B, second row, left panel).
BV(DR) chimeras with additional step-wise N-terminal Mo substitutions (i.e. BV(S170DR),
BV(YS170DR) and BV(LYS170DR) displayed no significant conversion in reactions seeded with
Mo protein-only recPrPSc (Fig 3A, rows 4–6; and Fig 3B, rows 3–5, right panel). In contrast,
BV(LDR) and BV(YDR) substrates were able to propagate Mo protein-only recPrPSc at ~1/3
the conversion efficiency of BV PrPC (Fig 3A, rows 7–8; and Fig 3B, rows 6–7, right panel).
Taken together, our results indicate that residues E227 and S230 are required for efficient con-
version of sPMCA reactions seeded by Mo protein-only recPrPSc, and additional substitutions
of other non-homologous residues also influence the degree of conversion efficiency.
Finally, we also designed and tested the ability of a series of chimeric constructs, which
substituted single Mo PrP amino acid residues to their cognate BV PrP residue, to propagate
Mo protein-only recPrPSc (Fig 4A and Fig 4B). This analysis showed that neither E227D nor
S230R substitution alone reduced the conversion efficiency of BV PrPC (Fig 4A, rows 3–4;
and Fig 4B, rows 1–2, right panel). On the other hand, BV(S170) and BV(L) displayed lower
conversion efficiencies than BV PrPC (Fig 4A, rows 5 and 7; and Fig 4B, rows 3 and 5, right
panel) These data indicate that the E227D and S230R substitutions work synergistically to
block propagation of Mo protein-only recPrPSc, whereas substitution of other individual resi-
dues can reduce the conversion efficiency of chimeric PrPC molecules.
The extreme C-terminal domain of BV PrPC is sufficient to propagate Mo
protein-only recPrPSc
We next sought to identify bank vole amino acid residue(s) that are sufficient to propagate Mo
protein-only recPrPSc. Therefore, we designed a series of chimeric constructs based on the Mo
PrPC backbone sequence that, working from the C- to the N-terminus, become progressively
substituted with BV PrP residues (Fig 5A). and tested the ability of these chimeric constructs
to be seeded by Mo protein-only recPrPSc in sPMCA reactions. The results show that substitu-
tion of the two non-homologous residues in extreme C-terminus (227 and 230) from DR to ES
is sufficient to propagate Mo protein-only recPrPSc (Fig 5B, first row; Mo(ES), right panel).
We also designed and tested the ability of a series of chimeric constructs that substitute single
BV PrP amino acid residues to their cognate Mo PrP residue to propagate Mo protein-only
recPrPSc (Fig 6A). The results show that this series of chimeric PrPC substrates are unable to prop-
agate Mo protein-only recPrPSc for three rounds in sPMCA (Fig 6B, right panels). In each case,
we observed a decrease in PK-resistant PrPSc over each round of sPMCA, resulting in the near
absence of PK-resistant PrPSc by round three in each reaction tested (Fig 6B, right panels). In
contrast, we found that the positive control RML PrPSc efficiently propagates in reactions this
series of chimeric PrPC substrates for three rounds of sPMCA (Fig 6B, left panels). Thus, no sin-
gle amino acid mutation from Mo to BV PrPC sequence is sufficient to restore the ability to propa-
gate Mo protein-only recPrPSc. Overall, our results show that both the E227D and S230R
substitutions are required to enable Mo PrPC chimeras to propagate Mo protein-only recPrPSc.
PLOS PATHOGENS Prion linchpin domain
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The extreme C-terminus also controls propagation of native infectious
prion strains
To evaluate whether 227 and 230 also controls the ability of PrPC substrate to propagate native
infectious prion strains, we tested the ability of hamster Sc237, sheep scrapie, and deer CWD
to seed the critical chimeric substrates affecting residues 227 and 230, BV(DR) and Mo(ES).
Like protein-only recPrPSc, all three of these native strains can seed BV but not Mo PrPC sub-
strate (Fig 7, top and third rows) (. Unlike BV PrPC, the BV(DR) chimera was unable to prop-
agate Sc237, sheep scrapie, or CWD (Fig 7, second row). Conversely, unlike Mo PrPC, the Mo
(ES) chimera was competent substrate for propagation of these three native strains (Fig 7, bot-
tom row). As expected, all of the wild-type and chimeric substrates could successfully propa-
gate mouse RML, a strain that infects both mice and bank voles efficiently (Fig 7, first seed
Fig 4. Determining the effect of single Mo amino acid mutations on the propagation of Mo protein-only recPrPSc.
(A) Table summarizing the effect of single Mo amino acid substitutions on the ability of BV/Mo PrPC chimeras to
propagate Mo protein-only recPrPSc. All constructs are based on the BV PrPC backbone. (B) Western blots of
experiments summarized in (A), showing three-round reconstituted sPMCA reactions using partially purified PrPC
substrates supplemented with PrP0/0 BH and seeded with various seeds, as indicated. -PK = samples not subjected to
proteinase K digestion; all other samples were proteolyzed.
https://doi.org/10.1371/journal.ppat.1008875.g004
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column). Taken together, these results indicate that residues 227 and 230 play a critical role in
determining the enhanced susceptibility of BV PrPC to seeding by a variety of native prion
strains.
In some reactions, we observed changes in the migration pattern of PK-resistant bands
between sPMCA rounds (Fig 7, RML- and sheep scrapie-seeded BVPrPC and CWD-seeded
Mo(ES)) These shifts may represent strain adaptation, which can occur rapidly and stochasti-
cally during sPMCA propagation [31], and which is more likely to occur during cross-species
propagation[32].
Specific PrPC glycosylation mutant is also able to propagate Mo protein-
only recPrPSc
Finally, we also sought to investigate the influence of PTMs (rather than amino acid sequence)
on PrPC susceptibility to Mo protein-only recPrPSc. To do this, we used brain homogenates
from transgenic mice expressing various mutant Mo PrPC molecules with specific PTM defects
as substrates in sPMCA reactions. We first analyzed a series of previously described glycosyla-
tion mutants with known differences in susceptibility to infection by various prion strains in
vivo[33]. Within this series, G1 mice express PrPC with a point mutation at the first N-linked
glycosylation site, G2 mice express PrPC with a point mutation at the second N-linked glyco-
sylation site, and G3 mice express PrPC containing both mutations[34, 35]. We carried out
sPMCA experiments using G1, G2, or G3 brain homogenate substrate seeded with Mo pro-
tein-only recPrPSc or RML. Remarkably, the results show that G2 PrPC was able to convert
into PrPSc when seeded by Mo protein-only recPrPSc (Fig 8, middle panel). The conversion
Fig 5. Determining the BV amino acids that are sufficient to propagate protein-only recPrPSc. (A)
Table summarizing the ability of BV/Mo PrPC chimeras to propagate Mo protein-only recPrPSc. All constructs are
based on the Mo PrPC backbone and become progressively substituted with BV residues from the C-terminus towards
the N-terminus. (B) Western blots of experiments summarized in (A), showing three-round reconstituted sPMCA
reactions using partially purified PrPC substrates supplemented with PrP0/0 BH and initially seeded with various seeds,
as indicated. -PK = samples not subjected to proteinase K digestion; all other samples were proteolyzed.
https://doi.org/10.1371/journal.ppat.1008875.g005
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process appears to be slower for G2 PrPC than for susceptible chimeric PrPC substrates, since
G2 PrPSc became detectable only after 4 rounds of sPMCA propagation. In contrast, neither
G1 nor G3 PrPC appeared to be susceptible to seeding by protein-only recPrPSc (Fig 8, top
and bottom panels).
Discussion
Here we leveraged a unique in vitro conversion system to identify a specific domain within the
prion protein (containing residues 227 and 230) that appears to serve as a linchpin that con-
trols the conformational change of PrPC to PrPSc. The amino acid sequences of mature bank
vole PrPC and mouse PrPC differ at only 8 residues[12, 13], and our system allowed us to sys-
tematically examine which of these non-homologous amino-acid residues are responsible for
the remarkable susceptibility of BV PrPC to convert into PrPSc. For the purposes of this study,
Fig 6. Determining the effect of single BV amino acid mutations on the propagation of Mo protein-only recPrPSc.
(A) Table summarizing the effect of single BV amino acid substitutions on the ability of BV/Mo PrPC chimeras to
propagate Mo protein-only recPrPSc. All constructs are based on the Mo PrPC backbone. (B) Western blots of
experiments summarized in (A), showing three-round reconstituted sPMCA reactions using partially purified PrPC
substrates supplemented with PrP0/0 BH and initially seeded with various seeds, as indicated. -PK = samples not
subjected to proteinase K digestion; all other samples were proteolyzed.
https://doi.org/10.1371/journal.ppat.1008875.g006
PLOS PATHOGENS Prion linchpin domain
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Fig 7. Determining the effect of specific BV and Mo amino acids on the species barrier. Western blots of
experiments showing three-round reconstituted sPMCA reactions using partially purified PrPC substrates
supplemented with PrP0/0 BH and initially seeded on day 0 with various seeds, as indicated. Day 0 samples are a seeded
reaction not subject to sonication. -PK = samples not subjected to proteinase K digestion; all other samples were
proteolyzed.
https://doi.org/10.1371/journal.ppat.1008875.g007
Fig 8. Propagation of Mo protein-only recPrPSc in sPMCA reactions with glycosylation-deficient PrPC substrates.
Western blots of sPMCA reactions using brain homogenates from glycosylation mutants G1, G2, or G3 as substrates,
as indicated. Reactions were seeded with Mo protein-only recPrPSc or RML, as indicated. -PK = samples not subjected
to proteinase K digestion; all other samples were proteolyzed. Mouse amino acid numbering scheme is used to show
locations of N-linked glycans on Mo PrP.
https://doi.org/10.1371/journal.ppat.1008875.g008
PLOS PATHOGENS Prion linchpin domain
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our system provided two critical technical advantages. (1) The ability of Mo protein-only
recPrPSc to convert BV PrPC does not depend on amino acid complementarity between seed
and substrate, allowing us to interpret our results without the potentially confounding factor
of sequence mismatch. (2) Our cell-based expression system allowed us to produce multiple
BV-Mo chimeric PrPC constructs rapidly and inexpensively, allowing us to perform a thor-
ough analysis of potential permutations in an unbiased manner.
Identification of a C-terminal “linchpin” domain that controls prion
protein conformational change
The major finding of this study is that the propensity of BV PrPC to undergo conformational
change to PrPSc appears to be primarily controlled by two residues (227 and 230) located
within the extreme C-terminus of mature PrP. Mutation of these two residues within the Mo
PrPC backbone to their corresponding BV sequence identities was sufficient to allow seeded
conversion of the resulting chimera by Mo protein-only recPrPSc. Conversely, mutation of
these same two residues within the BV PrPC backbone to their corresponding Mo sequence
identities largely inhibited conversion seeded by protein-only recPrPSc. Based on these find-
ings, we propose that the extreme C-terminal domain of PrPC may serve as a key “linchpin”
for its conformational change. We specifically infer that the E227 and S230 residues destabilize
this domain within BV PrPC to facilitate its conformational change into a variety of PrPSc con-
formers and prion strains. In support of this concept, we found that these two amino acids also
control susceptibility to hamster Sc237, sheep scrapie, and deer CWD prion strains. Notably,
Kobayashi et al. reported that ~40% of transgenic mice overexpressing Mo PrPC containing
the E227 and S230 mutations develop a spontaneous prion disease [36]. Taken together, the
results of our systematic analysis using seeded conversion assays and the spontaneous disease
reported by Kobayashi et al. provide complementary and compelling evidence for the hypothe-
sis that the extreme C-terminus is a linchpin domain, which controls the conversion (either
seeded or unseeded) of PrPC into PrPSc.
It is worth noting that, among the 8 BV residues that do not have homologous match in the
Mo PrP sequence, E227 and S230 are unique to vole species (Fig 1). In contrast, the other 6
mismatched BV residues can be found in other mammalian species; for instance, all 6 are
homologous to the corresponding residues within the hamster (Ha) PrP sequence (Fig 1).
Together, the observations that (1) residues E227 and S230 are unique to vole species and (2)
voles are uniquely susceptible to prion diseases[10–14] are consistent with the hypothesis that
the extreme C-terminus plays a key role in prion formation, possibly by stabilizing PrPC. This
hypothesis is also consistent with a number of previous results. (1) This region displays
decreased solvent accessibility upon transition from PrPC to PrPSc [37], indicating it undergoes
conformational change. (2) Residues 225 and 226 of deer PrPC (222 and 223 of BV PrPC)
appear to play critical roles in interspecies prion conversion [38]. (3) Specific polymorphisms
and mutations in the C-terminus can produce dominant negative PrPC molecules [39]. (4)
Y145stop, a PrP mutant lacking the C-terminus, appears to convert spontaneously into amy-
loid fibers[40] (the absence of the C-terminus in this truncated mutant may destabilize PrP
structure and promote misfolding). Finally, it is interesting to note that the GPI anchor is
attached to the C-terminus of PrP. It is possible that attachment to this bulky modification
may normally stabilize the C-terminal domain to prevent the conformational change of native
PrPC into PrPSc. Consistent with this notion, transgenic mice that overexpress Mo PrPC lack-
ing a GPI anchor spontaneously develop prion disease[41].
It is important to acknowledge the experimental limitations of our work. (1) We have not
confirmed that the various chimeric PrPSc molecules produced in our sPMCA reactions are
PLOS PATHOGENS Prion linchpin domain
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008875 September 8, 2020 11 / 22
infectious. However, we have previously shown that similar reactions containing BV PrPC sub-
strate and seeded with protein-only recPrPSc produces fully infectious prions[23], making it
likely that we are also studying a process relevant to infectious prion formation in this study. (2)
Since we are using Mo protein-only recPrPSc as a tool to study prion conversion, we can only
say that our results are sequence-independent, and may not hold for every prion strain (we have
only been able to test the few native strains that show differential ability to seed BV vs. Mo PrPC
substrate in reconstituted sPMCA reactions). Additional in vitro and in vivo studies are needed
to fully characterize the role played by the C-terminal domain in the propagation of naturally
occurring prion strains (3) Finally, our PrPC substrates are partially deglycosylated, and the gly-
cosylation status of PrPC has been shown to modulate its susceptibility to prion infection in vivo
[35, 42], raising the possibility that the deglycosylation step might artifactually change the results
of our chimeric analysis. However, this appears to be unlikely because we found that our par-
tially deglycosylated WT BV PrPC and Mo PrPC substrates display similar patterns of seeding
specificity as their fully glycosylated counterparts in sPMCA reactions.
The influence of other non-homologous residues on seeded conversion by
protein-only recPrPSc
In addition to identifying residues 227 and 230 as a linchpin domain, our work also showed
that other non-homologous residues could influence the ability of chimeric molecules to prop-
agate Mo protein-only recPrPSc. Specifically, we observed that additional substitution of either
M109L or N155Y partially restored the conversion ability of the BV(DR) chimera (Fig 3A,
rows 7–8), whereas additional substitution with N170S inhibited conversion of BV(DR) (Fig
3A row 4) as well as BV PrPC (Fig 4A, row 5). The former effects are expected outcomes of
increasing homology between substrate and seed in non-linchpin domains, but the latter effect
at residue 170 appears paradoxical, since increasing homology to the MoPrP sequence actually
reduces the ability of chimeric substrates to propagate Mo protein-only recPrPSc.
It has been previously reported that homology between PrPC and PrPSc at position 170 cor-
relates with interspecies prion conversion in vitro[43] and is important in allowing transmis-
sion across the species barrier in vivo[44]. Additionally, residues 155 and 170 have been shown
to control the conversion efficiency of BVPrPC in cell-free conversion (CFC) assays in vitro
[19] and control susceptibility to prion infection in rodents[17]. Surprisingly, our results para-
doxically show that increasing homology at position 170 between PrPC and PrPSc blocks con-
version with Mo protein-only recPrPSc. PrP forms a β2- α2 loop in the region 165–171[20],
and mutations that modify this structure can alter host susceptibility[45]. Mice, which have
serine at position 170, have a disordered loop [46, 47], while bank voles which have asparagine
at position 170 have a rigid loop [20]. Our data supports a model whereby structural or bio-
physical elements dictated by the amino acid sequence of PrPC that correlate with loop rigidity,
rather than amino acid sequence homology between PrPC and PrPSc, promote the conversion
of PrPC to PrPSc. This model is supported by our finding that a mutation that increases loop
homology but decreases rigidity blocks conversion by Mo protein-only recPrPSc together with
a series of observations from other investigators. (1) Transgenic mice that 2-3x overexpress
PrP containing 2 point mutations (170N,174T) that increase the rigidity of the a β2- α2 loop
develop a spontaneous prion disease[48]. (2) The 170N, 174T double mutation was also found
to increase the propensity of recPrP to form amyloid fibrils in vitro[49]. (3) Transgenic mice
overexpressing 3-5x PrP containing another mutation that increases the rigidity of the β2- α2
loop (D167S) develop a spontaneous neurologic disease [50].
It is worth noting that the impact of 170 substitution on PrP conversion is asymmetrical. In
other words, the inverse substitution (S170N) into the Mo PrPC backbone does not produce a
PLOS PATHOGENS Prion linchpin domain
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008875 September 8, 2020 12 / 22
chimera that is capable of propagating Mo protein-only recPrPSc (Fig 6A, row 5). We can
therefore infer that the extreme C-terminal domain likely plays a larger role than residue 170
in facilitating propagation of Mo protein-only recPrPSc.
PrPC glycosylation adjacent to C-terminus also inhibits prion conversion
In addition to the amino acid sequence of the extreme C-terminus, we found that the propen-
sity of PrPC to undergo prion conversion could also be affected by the adjacent N-linked gly-
can. Specifically, we found that mutant Mo PrPC lacking the second N-linked glycan (G2) at
position 196 (mouse numbering) near the C-terminus can also propagate mouse protein-only
recPrPSc in vitro. The effect of G2 deglycosylation does not appear to be as important as the
effect of the E227 and S230 mutations since G2 PrPSc formation was not observed until round
4. In contrast, mutant PrPC lacking the other (G1), or both (G3) N-linked glycans remained
resistant to conversion. It is surprising that Mo G2 PrPC should be more susceptible than Mo
G3 PrPC to seeding by Mo protein-only recPrPSc, since Mo G3 PrPC is more similar to recPrP
(in that both proteins are completely devoid of N-linked glycans). However, in line with our
results, it has been previously reported that transgenic mice expressing Mo G2 PrPC are more
susceptible than G1, G3, and wild-type mice to cross-species infection with human prions[33],
suggesting that the first N-linked glycan may serve to facilitate PrPSc formation for several dif-
ferent prion strains. However, the first N-linked glycan of PrPC may not be important for
propagating all prion strains (e.g. Kim et al. produced a synthetic prion strain is infectious to
mice expressing PrPC lacking both glycans[42]).
Conclusion
We have leveraged a unique in vitro conversion system to show that the extreme C-terminus
serves as a linchpin to control the seeded conversion of PrPC to PrPSc. Specifically, our data
indicate that BV-specific residues at positions 227 and 230 are sufficient to promote prion con-
version independent of seed/substrate sequence homology. We also found that the second N-
linked glycan (adjacent to the C-terminal domain) inhibits seeding by Mo protein-only
recPrPSc. While PrPC from both bank voles and G2 mutant mice are susceptible to conversion
by recombinant protein-only protein seeds and other natural strains, both are relatively resis-
tant to BSE-derived prions [17, 35], which is surprising since BSE prions readily infect wild-
type mice[51] and many other animal species. Taken together, these observations suggest that
Mo G2 PrPC and BV PrPC may share a common folding mechanism to form PrPSc, and that
this mechanism may be able to accommodate a wide variety of PrPSc conformations (except
for BSE, which may propagate by a different folding mechanism). It is possible that the G2 gly-
can, which is attached to residue N196, normally serves to stabilize the C-terminal domain of
PrPC, and that specific residues perform a similar function, such as D227 and R230 in mouse
PrP. Given that this linchpin controls the conversion of PrPC into PrPSc, we propose that stabi-
lization of this region potentially represents an attractive target for potential prion
therapeutics.
Materials and methods
Ethics statement
The Guide for the Care and Use of Laboratory Animals of the National Research Council was
strictly followed for all animal experiments. All experiments conducted at Dartmouth College
involving voles and mice in this study were conducted in accordance with protocol supa.su.1
as reviewed and approved by Dartmouth College’s Institutional Animal Care and Use
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Committee, operating under the regulations/guidelines of the NIH Office of Laboratory Ani-
mal Welfare (assurance number A3259-01) and the United States Department of Agriculture.
All experiments conducted at the Roslin Institute involving mice were approved by The Roslin
Institute’s Animal Welfare Ethical Review Board (internal protocol number; A471) and were
conducted according to the regulations of the 1986 United Kingdom Home Office Animals
(Scientific Procedures) Act.
Native prion strains
The mouse prion strain RML and the hamster prion strains 139H and sc237 were gifts from
Stanley Prusiner (University of California, San Francisco, USA). The deer CWD prion strain
and sheep scrapie prion strain were gifts from Mark Hall (USDA, Ames, Iowa, USA). The
hamster strain Hyper was a gift from Suzette Priola (Rocky Mountain Laboratories, Hamilton,
MT).
General sPMCA methods
The general sPMCA experimental method was adapted from Castilla et al.[52]. All PMCA
reactions were sonicated in microplate horns at 37˚C using a Misonix S-4000 power supply
(Qsonica, Newtown, CT) set to power 70 for three rounds. One round of PMCA is equal to 24
hr. The first round of PMCA was seeded with a volume of PrPSc equal to 10% of the total reac-
tion volume. RML prion-infected brain homogenates used as PrPSc seeds were used at a final
reaction concentration of 1.0% (v/v), and 139H prion-infected brain homogenates used as
PrPSc seeds were used at a final reaction concentration of 0.1% (v/v). To propagate the reaction
between PMCA rounds, 10% of the reaction volume was transferred into a new, unseeded,
substrate mixture. Due to the sensitivity of sPMCA[53], measures were undertaken to prevent
sample contamination. Sample conical tubes were sealed with Parafilm (Bemis Company, Osh-
kosh, WI) and the sonicator horn was soaked in 100% bleach between experiments to prevent
cross-contamination. The experimenter wore two pairs of gloves and changed the outer layer
of gloves when handling a new sample. Sample conical tubes were spun at 500 x g for 5 sec to
remove liquid off the conical tube lids before propagation and samples were propagated indi-
vidually using aerosol resistant pipette tips. With each experiment, a sentinel conical tube (a
conical tube containing the entire sPMCA reaction mixture but lacking seed) was also placed
in the sonicator horn to monitor reactions for contamination.
Preparation of cofactor and protein-only recPrPSc by sPMCA
RecPrP, purified as described by Breydo et al.[54] was used to generate cofactor recPrPSc and
protein-only recPrPSc, as described[7, 23]. Briefly, 200 μL reactions containing 6 μg/mL
recombinant mouse PrP 23–230 or M109 bank vole PrP 23–231 in conversion buffer [20 mM
Tris pH 7.5, 135 mM NaCl, 5 mM EDTA pH 7.5, 0.15% Triton X-100] were supplemented
with either brain-derived cofactor[7] for cofactor recPrPSc propagation, or water for protein-
only recPrPSc propagation. Reactions were seeded with 20 μL of converted cofactor recPrPSc
or protein-only recPrPSc and sonicated with 15 sec pulses every 30 min for 24 hr at 37˚C.
sPMCA with brain homogenate
A 10% (w/v) brain homogenate was prepared initially by Potter homogenization in PBS. The
crude homogenate was spun at 400 x g for 1 min, and the supernatant was removed and kept.
Triton X-100 was added to the supernatant for a final concentration of 1% (v/v), and the super-
natant was solubilized on ice for 10 min. Brains were taken from European bank voles with the
PLOS PATHOGENS Prion linchpin domain
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008875 September 8, 2020 14 / 22
M109 genotype, Syrian hamsters, C57BL/6J mice, PrP0/0 mice or transgenic mice expressing
glycosylation mutants (G1, G2, G3) as previously described[35]. One-hundred microliter reac-
tions were seeded with 10 μL of PrPSc and sonicated with 20 sec pulses every 30 min for 24 hr
at 37˚C.
Reconstituted sPMCA with HEK 293-expressed PrP
Fifty-five microliters of HEK expressed PrPC substrate was mixed with 10 μL of 10X cell
PMCA buffer (1% Triton X-100, 150 mM NaCl, 500 mM imidazole pH 7.5, 50 mM EDTA pH
7.5), 25 μL of 10% PrP0/0 brain homogenate, and seeded with 10 μL of a sPMCA reaction or
10% brain homogenate. One-hundred microliter reactions were seeded with 10 μL of PrPSc
and sonicated with 20 sec pulses every 30 min for 24 hr at 37˚C. The final concentration of
PrPC in each reaction was 4–5 μg/mL.
Detection of PrPSc in sPMCA reactions
Formation of PrPSc was monitored by digestion of PMCA samples with proteinase K (PK) and
western blotting. Samples were digested with 64 μg/mL PK (Roche, Basel, Switzerland) at 37˚C
with shaking at 750 r.p.m. Samples from sPMCA reactions using recPrP as the substrate were
treated for 30 min, while samples using HEK 293 expressed PrP or brain homogenate as the
substrate were treated for 60 min. Digestions were quenched by adding SDS-PAGE loading
buffer and heating to 95˚C for 15 min. SDS-PAGE and western blotting were performed as
described previously [7] using mAb 27/33. Twenty microliters of a sPMCA reaction was sub-
jected to PK digestion. The minus PK (-PK) lane is used to determine the conversion efficiency
of a sPMCA reaction. For reactions using recombinant PrP or crude BH as the substrate, the
-PK lane contains the same volume (20 μL) of a sPMCA reaction as a PK-digested sample. For
reactions using HEK 293 expressed PrP the -PK lane contains a volume (2 μL) equivalent to
one-tenth used in the PK-digested samples. This is because these substrates result in a much
lower expected conversion efficiency. Images were quantified using Image Studio Lite (Licor)
software to obtain the background-subtracted average signal intensity for the -PK and rounds
1–3 bands. The -PK value was multiplied by 10 to account for loading differences between it
and rounds 1–3. The percent-conversion was then calculated for round 3 by dividing the back-
ground-subtracted average signal intensity for each round by the background-subtracted aver-
age signal intensity for the -PK round. The average percent conversion ±SEM for round 3 was
calculated using between 1 and 5 biological replicates and 1 and 3 technical replicates.
We also confirmed that the final round PrPSc molecules produced in sPMCA reactions
using HEK-expressed PrPC substrates could subsequently seed bank vole brain homogenate
PMCA reactions (S3 Fig).
Mutagenesis and expression of HEK 293 PrP constructs
MoPrP on pcDNA 3.1 was generated by excising MoPrP from pcDNA5/FRT. BV PrP M109
pcDNA 3.1[23] and MoPrP pcDNA 5/FRT were cut using ApaI and HindIII (New England
Biolabs, Ipswich, MA, USA). MoPrP was then ligated into the pcDNA 3.1 backbone. Chimeric
constructs were generated using site directed mutagenesis using either the GeneTailor Site
Directed Mutagenesis System (Invitrogen, Carlsbad, CA, USA) or GeneArt Site Directed
Mutagenesis System (Invitrogen)(Table 1). All constructs were confirmed by sequencing. Con-
structs were then transfected into HEK 293 Freestyle-F cells (Invitrogen, Carlsbad, CA, USA)
[55]. After 48 hr, 320 mL of cells were harvested in 80 mL aliquots by spinning at 500 x g for 5
min and stored at -80˚C until purification.
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Table 1. Primers and template plasmids used to generate chimeric BV/Mo PrP plasmids.
CONSTRUCT TEMPLATE PLASMID PRIMERS
BV(DR) BV PrP pcDNA 3.1 F: AGTCCCAGGCCTACTACGATGGGAGAAG
ATCCCGCGCCGTGCTGCTCTTCTC
R: TCGTAGTAGGCCTGGGACTCCTTCT
GATACTG
BV(S170DR) BV(DR) F: CCGGTGGACCAGTACAGCAACCAGAA
CAACT
R: TGTACTGGTCCACCGGCCGGTAGT
ACACTT
BV(YS170DR) BV(S170DR) F: TACTACCGTGAAAACATGTACCGGTAC
CCTAA
R: CATGTTTTCACGGTAGTAGCGGTC
CTCC
BV(LYS170DR) BV(YS170DR) F: CAGTAAGCCAAAAACCAACCTGAAGCA
TGTGG
R: GTTGGTTTTTGGCTTACTGGGCTTG
TTCCACT
Mo(ES) Mo PrP pcDNA 5 F: TCAGGCCTATTACGAGGGGAGAAGCTC
CAGCAGC
R: GCTGCTGGAGCTTCTCCCCTCGTAATAG
GCCTGA
Mo(N155N170ES) Mo(N170ES) F: ACCGTGAAAACATGAACCGATATCCTAA
CCAAGTG
R: CACTTGGTTAGGATATCGGTTCATGTTTT
CACGGT
Mo(M109N155N170ES) Mo(N155N170ES) F: CCAAAAACCAACATGAAGCACGTGGCA
GG
R: CCTGCCACGTGCTTCATGTTGGTTTTTGG
BV(R) BV PrP pcDNA 3.1 F: TACTACGAAGGGAGAAGATCCCGCGCC
GTGCT
R: AGCACGGCGCGGGATCTTCTCCCTTCGTA
GTA
BV(D) BV PrP pcDNA 3.1 F: CCCAGGCCTACTACGACGGGAGAAGTT
CCC
R: GGGAACTTCTCCCGTCGTAGTAGGCCT
GGG
BV(S170) BV PrP pcDNA 3.1 F: GTGGACCAGTACAGCAACCAGAACAAC
R: GTTGTTCTGGTTGCTGTACTGGTCCAC
BV(Y) BV PrP pcDNA 3.1 F: ACCGTGAAAACATGTACCGGTACCCTAA
CC
R: GGTTAGGGTACCGGTACATGTTTTCACG
GT
BV(L) BV PrP pcDNA 3.1 F: GCCAAAAACCAACCTGAAGCATGTGGCA
G
R: CTGCCACATGCTTCAGGTTGGTTTTTGGC
Mo(S) Mo PrP pcDNA 5 F: TTACGACGGGAGAAGCTCCAGCAGCAC
R: GTGCTGCTGGAGCTTCTCCCGTCGTAA
Mo(E) Mo PrP pcDNA 5 F: CAGGCCTATTACGAGGGGAGAAGATCC
AGCA
R: TGCTGGATCTTCTCCCCTCGTAATAGGC
CTG
Mo(N170) Mo PrP pcDNA 5 F: GTGGATCAGTACAATAACCAGAACAACT
TCG
R: CGAAGTTGTTCTGGTTATTGTACTGATC
CAC
(Continued)
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Purification of HEK 293 expressed PrP constructs
Pellets thawed on ice were re-suspended in 20 mL of lysis buffer [20 mM MOPS pH 7.0, 0.15
M NaCl, 1% Triton X-100, 1% DOC, CompleteTM mini EDTA-free protease inhibitor (Roche,
Basel, Switzerland)]. The mixture was solubilized on ice for 30 min, then centrifuged at
100,000 x g for 35 min. The solubilized supernatant was applied to a 2 mL IMAC copper sulfate
column made with chelating Sepharose (GE Healthcare, Chicago, USA) that was pre-equili-
brated with equilibration and wash buffer [20 mM MOPS pH 7.0, 0.15 M NaCl, 10 mM imid-
azole, 1% Triton X-100]. The column was then washed with 20 mL of equilibration and wash
buffer. The sample was eluted with 8 mL of elution buffer [20 mM MOPS pH 7.5, 0.15 M
NaCl, 0.15 M imidazole pH 7.0, 1% Triton X-100]. The eluate was diluted 1:1 with pre-SP
buffer [20 mM MES pH 5.4, 0.15 M imidazole pH 7.0, 0.15 M NaCl, and 1% Triton X-100].
Next, the eluate was applied over a 2 mL SP Sepharose fast flow (Sigma-Aldrich, St. Louis,
MO, USA) exchange column pre-equilibrated with SP wash buffer [20 mM MOPS pH 7.0, 250
mM NaCl, and 1% Triton X-100]. The column was washed with 10 mL SP was buffer and
eluted with 8 mL SP elution buffer [20 mM MOPS pH 7.5, 500 mM NaCl, and 1% Triton X-
100]. The eluate was then partially deglycosylated by adding 80 μL of Glycerol Free PNGase F
(New England Biolabs, Ipswich, MA, USA) to 8 mL of eluate. The mixture was incubated for
24 hr at 37˚C with shaking at 350 r.p.m. The partially deglycosylated substrate was then con-
centrated and repurified by applying over a 400 μL copper column pre-equilibrated with equil-
ibration and wash buffer. The column was washed with 20 mL of equilibration and wash
buffer and eluted with 2 mL of IMAC-CuSO4-elution buffer [20 mM MES pH 6.4, 0.15 M
imidazole pH 7.0, 150 mM NaCl, and 1% Triton X-100]. The eluate was loaded into a 3500
MWCO Slide-A-Lyser (Thermo Fisher, Waltham, MA, USA) and dialyzed overnight into dial-
ysis buffer [44].
To ensure that substitutions near the C-terminus of PrPC do not interfere with addition of
the C-terminal GPI-anchor, we treated chimeric PrPC molecules with either single or double
C-terminal substitutions with PI-PLC (S4 Fig). It has been previously reported that PI-PLC
treatment of GPI-anchored proteins such as PrPC cause the treated proteins to bind less well
to PVDF membranes and migrate more slowly than untreated controls [56]. Accordingly, we
observed that all of the HEK-expressed PrPC chimeras tested, as well as HEK-expressed BV
PrPC native brain PrPC immunopurified from mouse brain, showed displayed slower migra-
tion and lower intensity on western blot after PI-PLC treatment (S4 Fig). In contrast,
Table 1. (Continued)
CONSTRUCT TEMPLATE PLASMID PRIMERS
Mo(N155) Mo PrP pcDNA 5 F: ACCGTGAAAACATGAACCGATATCCTAA
CCAAGTG
R: CACTTGGTTAGGATATCGGTTCATGTTTT
CACGGT
Mo(M109) Mo PrP pcDNA 5 F: CCAAAAACCAACATGAAGCACGTGGCAG
G
R: CCTGCCACGTGCTTCATGTTGGTTTTTGG
BV(LDR) BV(DR) F: CAGTAAGCCAAAAACCAACCTGAAGCAT
GTGG
R: GTTGGTTTTTGGCTTACTGGGCTTG
TTCCACT
BV(YDR) BV(DR) F: TACTACCGTGAAAACATGTACCGGTACC
CTAA
R: CATGTTTTCACGGTAGTAGCGGTCC
TCC
https://doi.org/10.1371/journal.ppat.1008875.t001
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bacterially-expressed recPrP, which lacks a GPI-anchor, is apparently unaffected by PI-PLC
treatment (S4 Fig). Thus, all of the chimeric PrPC substrates used in this study appear to have
proper post-translational modifications (S1 Fig and S4 Fig) and folding (as judged by solubil-
ity in non-denaturing solution and normal behavior during IMAC and ion exchange chroma-
tography. These observations indicate that substitution of homologous residues between
mouse and bank vole PrPC does not cause aberrant metabolism or trafficking of chimeric mol-
ecules in HEK 293 cells.
Supporting information
S1 Fig. Expression and partial enzymatic deglycosylation of PrPC in FreestyleTM HEK 293
cells. Western blots showing PrP partially purified from cell lysates expressing the indicated
protein, or no protein, before and after partial enzymatic deglycosylation with PNGase F
(+ PF), as indicated. (A) Wild-type constructs. (B) Chimeric constructs.
(TIF)
S2 Fig. Effect of partial enzymatic deglycosylation of PrPC substrate on its ability to prop-
agate mouse prions. Western blots showing three-round reconstituted sPMCA reactions
using partially purified Mo PrPC substrate supplemented with PrP0/0 BH and seeded with
mouse RML. Substrates were either untreated or partially deglycosylated with PNGase F dur-
ing purification, as indicated. -PK = samples not subjected to proteinase K digestion; all other
samples were proteolyzed.
(TIF)
S3 Fig. Brain homogenate PMCA reactions seeded with chimeric PrPSc molecules. West-
ern blots showing PMCA reactions using crude bank vole brain homogenate substrate seeded
with various HEK-expressed PrPSc molecules, as indicated. The chimeric PrPSc molecules are
final round products of 3-round sPMCA reactions using HEK-expressed PrPC substrates origi-
nally seeded with Mo protein-only recPrPSc or buffer, as indicated.
(TIF)
S4 Fig. PI-PLC treatment of purified PrP substrates. Western blots of various purified PrP
substrates (bacterially-expressed recPrP, immunopurified native brain PrPC, different HEK-
expressed PrPC chimeras with substitutions at residues 227 and/or 230 as indicated, or HEK
expressed bank vole PrPC) treated either with (+) or without (-) 0.25U/mL Phosphoinositide
phospholipase C (PI-PLC) for 14 hr at 37 oC with shaking at 800 r.p.m. as indicated. Proteins
were transferred from a 12.5% polyacrylamide gel onto a Millipore Immobilon-P PVDF mem-
brane by semi-dry electroblotting, and probed with mAb 27/33.
(TIF)
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